Cantor Fitzgerald Forecasts BBIO FY2026 Earnings

BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) - Research analysts at Cantor Fitzgerald issued their FY2026 earnings per share (EPS) estimates for BridgeBio Pharma in a report released on Monday, June 9th. Cantor Fitzgerald analyst J. Schimmer forecasts that the company will post earnings per share of ($3.32) for the year. Cantor Fitzgerald currently has a "Overweight" rating and a $95.00 price target on the stock. The consensus estimate for BridgeBio Pharma's current full-year earnings is ($3.67) per share.

BridgeBio Pharma (NASDAQ:BBIO - Get Free Report) last released its quarterly earnings results on Tuesday, April 29th. The company reported ($0.88) EPS for the quarter, topping analysts' consensus estimates of ($1.00) by $0.12. The company had revenue of $36.74 million during the quarter, compared to analysts' expectations of $57.14 million. BridgeBio Pharma's quarterly revenue was down 44.8% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.20) EPS.

BBIO has been the subject of several other research reports. Redburn Atlantic initiated coverage on BridgeBio Pharma in a research note on Monday, March 31st. They set a "buy" rating and a $50.00 price target for the company. JPMorgan Chase & Co. upped their target price on BridgeBio Pharma from $44.00 to $50.00 and gave the stock an "overweight" rating in a research note on Monday, March 24th. UBS Group lifted their price target on shares of BridgeBio Pharma from $65.00 to $72.00 and gave the stock a "buy" rating in a research note on Wednesday, April 30th. Wall Street Zen raised shares of BridgeBio Pharma from a "sell" rating to a "hold" rating in a research note on Saturday, June 7th. Finally, Scotiabank increased their target price on shares of BridgeBio Pharma from $52.00 to $55.00 and gave the company a "sector outperform" rating in a report on Wednesday, April 30th. Two investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $57.36.

BridgeBio Pharma Stock Up 0.7%

NASDAQ:BBIO traded up $0.26 during midday trading on Wednesday, hitting $39.31. The company had a trading volume of 650,703 shares, compared to its average volume of 2,474,306. The company has a market capitalization of $7.46 billion, a PE ratio of -13.79 and a beta of 1.10. BridgeBio Pharma has a 52-week low of $21.62 and a 52-week high of $40.40. The stock's fifty day moving average price is $34.92 and its 200-day moving average price is $32.91.

Insider Buying and Selling at BridgeBio Pharma

In other BridgeBio Pharma news, Director Hannah Valantine sold 4,292 shares of the company's stock in a transaction on Tuesday, June 10th. The shares were sold at an average price of $40.00, for a total value of $171,680.00. Following the completion of the transaction, the director now directly owns 1,764 shares in the company, valued at approximately $70,560. This represents a 70.87% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CAO Maricel Apuli sold 1,026 shares of the business's stock in a transaction dated Friday, May 2nd. The shares were sold at an average price of $38.51, for a total transaction of $39,511.26. Following the transaction, the chief accounting officer now owns 147,639 shares in the company, valued at $5,685,577.89. This represents a 0.69% decrease in their position. The disclosure for this sale can be found here. Insiders sold 6,396,474 shares of company stock valued at $219,332,971 in the last 90 days. Insiders own 18.20% of the company's stock.

Institutional Trading of BridgeBio Pharma

Hedge funds and other institutional investors have recently modified their holdings of the business. Steward Partners Investment Advisory LLC boosted its stake in BridgeBio Pharma by 85.8% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 1,022 shares of the company's stock worth $28,000 after acquiring an additional 472 shares in the last quarter. GAMMA Investing LLC increased its position in BridgeBio Pharma by 71.0% during the 1st quarter. GAMMA Investing LLC now owns 920 shares of the company's stock valued at $32,000 after buying an additional 382 shares in the last quarter. Jones Financial Companies Lllp bought a new position in BridgeBio Pharma during the 1st quarter valued at approximately $35,000. Itau Unibanco Holding S.A. purchased a new position in BridgeBio Pharma during the fourth quarter valued at $41,000. Finally, Sterling Capital Management LLC raised its stake in BridgeBio Pharma by 554.6% during the fourth quarter. Sterling Capital Management LLC now owns 1,787 shares of the company's stock valued at $49,000 after buying an additional 1,514 shares during the last quarter. 99.85% of the stock is owned by hedge funds and other institutional investors.

About BridgeBio Pharma

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.